Strategic partnerships Marinomed has a track record of collaboration, including partnerships with Gaia Healthcare in the Gulf region and Nice & Green, plus a recent term sheet with Phargentis SA. This indicates openness to licensing, co-development, and formulation service partnerships that could be expanded to respiratory and ophthalmic indications leveraging Marinosolv.

Marinosolv value proposition The Marinosolv platform enhances solubility and bioavailability of poorly soluble compounds, enabling novel therapies. This positions Marinomed well for in-licensing or joint development opportunities for refractory immune-related and inflammatory targets in respiratory or ocular diseases.

OTC portfolio shift Carragelose-based OTC business was sold to Unither Pharmaceuticals in 2025, suggesting a strategic refocus on higher-value drug development. Potential buyers or partners for continued OTC-adjacent products or derivatives could present near-term sales avenues or milestone-based collaborations.

Financial and leadership signals With modest current revenue and ongoing funding activities, plus a CFO transition in 2025 and new investor relations leadership in 2024, there is a clear signal of investor-driven growth. This environment may be conducive to partner-led financing, milestone-driven deals, and revenue-sharing collaborations.

Market expansion opportunities Active engagement with potential expansion regions (Gulf collaboration, European base in Austria) and a stated aim of global marketed therapeutics indicate opportunities to introduce Marinosolv-enabled formulations to new regional regulatory environments, with potential for regional development contracts or co-commercialization.